STAT+: What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s surprising rise

Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks